Gladstone Institutional Advisory’s Cardiff Oncology CRDF Stock Holding History

Gladstone Institutional Advisory’s Portfolio CRDF Stock Details CRDF Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$16.9K	Hold	13,000	–	–	﹤0.01%	889
2026 Q1	$21.1K	Hold	13,000	–	–	﹤0.01%	827
2025 Q4	$36.5K	Hold	13,000	–	–	﹤0.01%	785
2025 Q3	$26.8K	Hold	13,000	–	–	﹤0.01%	782
2025 Q2	$41K	Hold	13,000	–	–	﹤0.01%	749
2025 Q1	$40.8K	Hold	13,000	–	–	﹤0.01%	710
2024 Q4	$56.4K	Sell	13,000 -2,000	-13%	-$6.25K	﹤0.01%	692
2024 Q3	$40K	Hold	15,000	–	–	﹤0.01%	677
2024 Q2	$33.3K	Hold	15,000	–	–	﹤0.01%	654
2024 Q1	$80.1K	Hold	15,000	–	–	﹤0.01%	627
2023 Q4	$22.2K	Hold	15,000	–	–	﹤0.01%	663
2023 Q3	$20.9K	Buy	15,000 +1,000	+7%	+$1.69K	﹤0.01%	616
2023 Q2	$20.6K	Hold	14,000	–	–	﹤0.01%	625
2023 Q1	$23.1K	Hold	14,000	–	–	﹤0.01%	648
2022 Q4	$19.6K	Hold	14,000	–	–	﹤0.01%	638
2022 Q3	$22K	Buy	+14,000	New	+$33.7K	﹤0.01%	625

Other funds holding CRDF

LCM

Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Pfizer New York $170M AUM 191.09% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

William Blair & Company Chicago, Illinois $38.4B AUM 25.71% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Gladstone Institutional Advisory's CRDF Position: Q2 2026 in Review

Gladstone Institutional Advisory held its Cardiff Oncology (CRDF) position steady in Q2 2026 at 13,000 shares worth $16.9K. The position accounts for ﹤0.01% of the portfolio, ranked #889.

Gladstone Institutional Advisory first reported a position in CRDF in Q3 2022 and has held it in 16 quarters since. The position peaked at $80.1K in Q1 2024. 105 funds tracked by Wall St. Rank hold CRDF as of Q2 2026.

Gladstone Institutional Advisory held 13,000 shares of Cardiff Oncology worth $16.9K as of Q2 2026.
Gladstone Institutional Advisory left its Cardiff Oncology share count unchanged in Q2 2026.
Cardiff Oncology made up ﹤0.01% of Gladstone Institutional Advisory's portfolio in Q2 2026, its #889 holding.
Gladstone Institutional Advisory first reported a position in Cardiff Oncology in Q3 2022 and has held it in 16 quarters since.
Gladstone Institutional Advisory's Cardiff Oncology position peaked at $80.1K in Q1 2024.
105 funds tracked by Wall St. Rank held Cardiff Oncology as of Q2 2026.

Based on Gladstone Institutional Advisory's 13F filing for Q2 2026, filed 27 Jul 2026.